Kmart Corp. agreed to pay $35.3 million to the federal government and a number of states to settle a whistleblower lawsuit.
A judge overturned a $150 million verdict against AbbVie, the first resulting from lawsuits claiming the company fraudulently misrepresented the risks of AndroGel.
Ocular Therapeutix Inc. said the U.S. Securities and Exchange Commission (SEC) issued a subpoena seeking information about the company’s eye-pain drug Dextenza.
Novartis drug Tasigna is approved by FDA as first CML therapy with Treatment-free Remission data in its label
Novartis announced that the FDA approved the inclusion of Treatment-free Remission data in the Tasigna (nilotinib) U. S. product label.
Canadian drugmaker Valeant Pharmaceuticals International Inc. said the U.S. Food and Drug Administration approved Lumify drop to treat eye redness.
Shares of Celgene plunged after the company announced Revlimid combined with Biogen’s Rituxan failed in a late-stage study of previously untreated patients with follicular lymphoma.
Shares of Agile Therapeutics plunged more than 62 percent in early trading after the company announced that the U.S. FDA rejected its low-dose hormonal contraceptive patch called Twirla.
The U.S. Food and Drug Administration said it plans to let medical device makers report less serious malfunctions of some devices on a quarterly basis to cut down on repeated reviews of common problems.
The U.S. FDA granted priority review for Novartis’ Tafinlar in combination with Mekinist for treating some patients with advanced melanoma.